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It is now established that activation of two vasopressin 
receptors located in the circulation, V1-R and V2-R, 
causes opposite vascular eﬀ  ects; that is, vasoconstriction 
and vasodilation, respectively. Hence, Rehberg and 
colleagues examined whether a V2-R blocker may 
prevent vasodilation and help maintain cardiovascular 
homeostasis during septic shock [1].
Vasopressin has long been recognized to have very 
potent vasoconstrictor action in isolated vascular 
preparations, but when infused in vivo under normal 
conditions vasopressin increases blood pressure only 
modestly at best. In addition, development of vaso-
pressin’s vasocon  striction blockers a few decades ago 
showed them to be ineﬀ   ective in lowering the blood 
pressure of most forms of hypertension. Unsurprisingly, 
therefore, there was little interest in vasopressin’s 
vascular action until our report that some patients with 
prolonged vasodilatory shock had inappropriately low 
plasma vasopressin levels and that administration of 
exogenous hormone quickly restored blood pressure [2].
Like most hormones involved in blood pressure and 
extracellular ﬂ   uid control, however, vasopressin has 
several receptors that regulate diﬀ  erent  functions. 
Vasopressin’s vasoconstriction action is mediated by the 
V1a receptor, V1a-R, located in vascular smooth muscle. 
Th  e second vasopressin receptor (V2-R) is abundantly 
present in the collecting duct, where it mediates the 
hormone’s antidiuretic action. While the role of this 
receptor outside the kidney is less well understood, it is 
known to be located in the endothelium and 
pharmacological studies have shown that its speciﬁ  c 
activation in the circulation induced vasodilation and 
hypotension and the release of the coagulation factors 
VIIIc and von Willebrand factor. Th  ese  ﬁ  ndings suggest 
that the use of vasopressin as a pressor in clinical 
medicine could be made safer and perhaps more eﬀ  ective 
using selective activation of V1a-R or blockade of V2-R.
In this regard, in two recent studies where a selective 
V1a-R agonist was compared with exogenous vasopressin 
during septic shock, the former was found to be of 
superior beneﬁ  t than the natural hormone, which, need-
less to say, stimulated both V1a-R and V2-R [3,4]. Th  ese 
provocative experiments suggested that administration 
of exogenous vasopressin to maintain blood pressure in 
septic shock is complicated by stimulation of receptors 
with conﬂ  icting function. Moreover, because – as in the 
early phase of sepsis – endogenous plasma vasopressin 
can reach exceedingly high levels [5], it is also possible 
that stimulation of the V2-R by endogenous hormone 
could in fact contribute to the disease process.
Accordingly, Rehberg and colleagues examined the 
hypothesis that administration of a V2-R-speciﬁ  c blocker 
during the early phase of septic shock may have a 
beneﬁ  cial eﬀ  ect (that is, be more eﬀ  ective in maintaining 
cardiovascular homeostasis than placebo) or may be 
superior to administration of exogenous vasopressin. 
Brieﬂ   y, they induced septic shock in sheep by intra-
peritoneal injection of feces and, upon development of 
hypotension, animals were randomly assigned to receive 
vehicle, vasopressin or the V2-R antagonist [1]. If needed, 
animals were given open-label norepinephrine to 
maintain mean arterial pressure at ~70 mmHg. Th  e  study 
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important results. First, the amount of norepinephrine 
needed to maintain mean arterial pressure was no 
diﬀ   erent among the groups. Th  ere was a statistically 
signiﬁ  cant increase, however, in the survival time for the 
group of animals receiving the V2-R blocker when 
compared with those receiving placebo or receiving vaso-
pressin. In concordance with this ﬁ  nding, the animals 
treated with the V2-R antagonist displayed less severe 
lactic acidosis as well as oxidative stress. Finally, the 
authors made the intriguing observation that the plasma 
levels of vaso  pressin were markedly reduced in the 
animals receiving the V2-R blocker.
What are we to make of these observations? Since the 
dose of norepinephrine needed to maintain blood 
pressure was similar in all groups, we can conclude that 
in the early phase of septic shock – when plasma levels of 
vasopressin were endogenously increased (in the animals 
receiving placebo) or increased by administration of 
exogenous hormone – a potential vasodilator action of 
the V2-R is unlikely to have contributed to determine the 
blood pressure. Had this been the case, the animals 
receiving the V2-R blocker would have required less 
norepinephrine. Nonetheless, this group of animals had 
longer survival as well as metabolic evidence of less 
severe disease. Th   e explanation for this beneﬁ  t is a matter 
of speculation: improved cardiovascular homeostasis 
(higher left ventricle stroke index and central venous and 
pulmonary artery occlusion pressures with V2-R block-
ade were observed); inhibition of vein dilatation; preven-
tion release of coagulation factors thereby retarding 
development of capillary thrombosis; and reduction of 
endo  thelial nitric oxide release with diminution of 
reactive oxygen species.
Concerning the very interesting ﬁ   nding that plasma 
vasopressin levels dramatically decreased in animals with 
V2-R blockade, as Rehberg and colleagues note, in vitro 
experiments [6] and in vivo experiments [7] indicate that 
vasopressin has a positive feedback on its own secretion 
that appears to be V2-R mediated. Th   is intriguing ﬁ  nding 
needs conﬁ  rmation.
In sum, this work is a valuable addition to the emerging 
literature on the mechanisms of action of vasopressin 
during septic shock and highlights for the ﬁ  rst time a role 
of V2-R. Th   is work makes it clear that future research on 
vasopressin’s role in septic shock needs to take into 
account the precise vasopressin receptors that are 
stimulated and/or inhibited.
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